CustoMED raises $6 million for AI-assisted, 3D-printed surgical tools

The Israeli medtech startup CustoMED announces the closing of a seed round totaling $6 million. Participants include Longevity Venture Partners, Varana Capital, Flag Capital, the Israel Innovation Authority, an orthopedic implant manufacturer, and Avishai Abrahami. The company plans to use the capital to expand its platform for patient-specific orthopedic applications and to prepare regulatory steps in the U.S. and EU, with approvals starting in 2026.

At the core of the offering is a cloud-based, “surgeon-first” pipeline that combines artificial intelligence and automation with 3D printing. Starting from the surgeon’s preoperative plan, the software generates specific cutting and drilling guides as well as implant variants within minutes and converts them into printable datasets. Manufacturing is carried out on demand in the hospital or via certified partners. The goal is consistent integration into existing OR workflows, including documentation and traceability.

“CustoMED’s patient-specific surgical tools enable more precise orthopedic surgeries through affordable, real-time solutions delivered directly into the operating room,” said Or Benifla, Co-founder of CustoMED. “By putting scalable, personalized technology directly in surgeons’ hands, our mission is to make computer-guided surgery fast, accessible, and routine, transforming what was once a boutique process into standard of care for every patient.”

CustoMED emerged from the 3D Printing & Innovation Lab at Sheba Medical Center, established in 2018 by Dr. Dina Orkin together with the future founders. The startup is part of the hospital’s ARC innovation ecosystem.

“CustoMED is embedding precision and surgeon-directed tools into everyday workflows, shortening the path from imaging to the operating room while preserving governance, quality, and safety,” said Prof. Eyal Zimlichman, Founder and Director of ARC Innovation and Chief Innovation, Transformation, and AI Officer at Sheba Medical Center. “The company exemplifies ARC’s mission to translate clinical insight into scalable, real-world impact.”

“We were immediately impressed by the ARC team’s world-class experience and CustoMED’s mission to improve surgical performance and patient outcomes,” added Raissa Hacohen, Managing Partner at Longevity Venture Partners. “CustoMED’s platform gives surgeons everywhere access to personalized planning and surgical tools that can raise the standard of care in orthopedic surgery.”

Investors also view the potential positively: according to Raissa Hacohen of Longevity Venture Partners, the platform opens access to personalized planning and tools for a broad range of surgeons.

With the financing, CustoMED plans to automate additional orthopedic indications and roll out the on-demand manufacturing model internationally. The approach aims to establish patient-specific 3D-printed parts as a standardized component of orthopedic care.